Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial.

ABSTRACT:

Background

Immunoglobulin E (IgE) and immunoglobulin G4 (IgG4) to peanut and its components may influence the clinical reactivity to peanut. Allergen-specific immunotherapy is known for modifying both IgE and IgG4. Peanut oral immunotherapy may influence these serological parameters.

Methods

Exploratory analyses of serological data from participants receiving peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) and placebo in the double-blind, randomized, phase 3 PALISADE trial were conducted to evaluate potential relationships between peanut-specific and peanut component-specific (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, and Ara h 9) IgE and IgG4 levels and clinical outcomes.

Results

A total of 269 participants (PTAH, n = 202; placebo, n = 67) were analyzed. No

SUBMITTER: Nilsson C 

PROVIDER: S-EPMC10793676 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature